Datapoint: BMS Asks Supreme Court to Rehear CAR-T Dispute

Bristol Myers Squibb is once again asking the United States Supreme Court to rehear its CAR-T patent dispute against Gilead Sciences. The high court already declined to hear the case, which asks for the reinstatement of a $1.2 billion award to BMS, earlier this month, but the drugmaker is asking again in light of Amgen’s revived Repatha patent case. BMS and Gilead’s CAR-T therapies, Breyanzi and Yescarta, are currently approved to treat certain forms of lymphoma. Breyanzi holds covered or better status for 31% of all insured lives under the pharmacy benefit, and 83% under the medical benefit, compared to Yescarta’s coverage rates of 29% and 86%.

SOURCE: MMIT Analytics, as of 11/30/22

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 20

Datapoint: Ipsen’s Latest Accelerated Approval Will Challenge Intercept’s Ocaliva

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 18

Datapoint: Texas Won’t Halt Latest Medicaid Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 17

Datapoint: Oscar Plans to Double Enrollment by 2027

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today